Company Overview - Junshi Biosciences is located in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with main business revenue comprising 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [2] Financial Performance - For the first half of 2025, Junshi Biosciences achieved a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2] Shareholder Structure - As of June 30, 2025, the number of shareholders of Junshi Biosciences increased by 5.88% to 31,200, with an average of 24,543 circulating shares per person, a decrease of 5.56% from the previous period [2] Market Activity - On September 18, Junshi Biosciences saw a trading volume of 909 million yuan, with a net financing purchase of 19.83 million yuan, indicating strong market interest [1] - The financing balance reached 1.422 billion yuan, accounting for 4.06% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of financing activity [1] Institutional Holdings - As of June 30, 2025, major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with changes in their holdings reflecting varying levels of institutional interest [3]

Core Insights - The conference highlighted the growing global competitiveness of Chinese innovative drugs, particularly in areas like ADC and bispecific antibodies, while emphasizing the need for improvement in original innovation capabilities [1][5][6] - There is a consensus among industry leaders that "going global" is essential for the future of Chinese innovative drugs, with calls for more supportive policies to facilitate this process [1][7][9] Group 1: Current State of Chinese Innovative Drugs - Chinese innovative drugs have reached a global competitiveness level from "1 to 10," especially in engineering fields, but still need to enhance original innovation from "0 to 1" [1] - The quality of projects is crucial for international expansion, as highlighted by industry leaders who stress that strong data and comprehensive packages are essential for success [2][3] - The past decade has seen significant development in the Chinese innovative drug ecosystem, with a complete industrial chain now in place, particularly in cities like Shanghai [4] Group 2: Challenges and Opportunities - The domestic market's limitations are pushing companies to explore international markets, with a focus on countries involved in the Belt and Road Initiative [7] - There is a need for policy reforms regarding listing standards to support innovative drug companies that face long development cycles and high R&D costs [7][9] - The current pricing of innovative drugs in international markets is still influenced by domestic prices, which poses challenges for global competitiveness [9] Group 3: Future Directions and Innovations - The industry is witnessing a surge in various therapeutic areas, including small molecules, antibodies, peptides, RNA, and gene therapies, indicating a diverse landscape of innovation [10] - The potential for small nucleic acids and other novel therapies is recognized as a significant opportunity for Chinese companies to lead in the global market [10] - Industry leaders express confidence in the future of Chinese innovative drugs, anticipating that with time, more companies will emerge as global players [11]

作为科创板迈向"新高地"暨"硬科硬客"2025年会的重要内容之一，9月10日，君实生物（688180.SH）、 皓元医药（688131.SH）、药康生物（688046.SH）、美迪西（688202.SH）、迈威生物（688062.SH） 等科创板创新药领域龙头上市公司高管，逾50家机构投资者参与了创新药产业链的高层次闭门研讨会。 会议围绕中国创新药出海的核心能力、国际竞争力现状及未来发展方向进行深入研讨。 与会嘉宾认为，中国创新药已具备从"1到10"的全球竞争力，尤其在ADC、双抗等工程化领域国际领 先，但在"0到1"的原始创新方面仍需努力。出海，成为行业共识，企业呼吁政策进一步支持破解"出 海"难题。 "君实生物是最早把国际化当作自己重要战略的本土企业之一，特瑞普利单抗也是第一个获得美国FDA 批准上市的中国自研自产PD-1产品，目前已经在40个国家和地区获批。"李鑫坦言，产品出海是高成本 的事情，需要满足国际上未被满足的需求，同时要应对FDA等海外监管机构的严格审评，包括临床和生 产端。 皓元医药董事长兼总经理郑保富从产业链角度分析："创新药是我们CRO（定制研发机构）、CDMO （医药合同定制研发生产企 ...

两融数据显示，该股最新融资余额为14.03亿元，近5日增加5311.18万元，增幅为3.94%。（数据宝） 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报·数据宝统计显示，君实生物-U今日收盘价为45.73元，上涨0.20%，日换手率为2.57%，成交额为9.09亿元，全天主力资金净流出3762.49万元，近5日该股累计下跌4.19%，近5日 君实生物-U9月18日大宗交易平台出现一笔成交，成交量100.00万股，成交金额4541.00万元，大宗交易成交价为45.41元，相对今日收盘价折价0.70%。该笔交易的买方营业部为方正证券股 9月18日君实生物-U大宗交易一览 ...

两融数据显示，该股最新融资余额为14.03亿元，近5日增加5311.18万元，增幅为3.94%。（数据宝） 9月18日君实生物-U大宗交易一览 君实生物-U9月18日大宗交易平台出现一笔成交，成交量100.00万股，成交金额4541.00万元，大宗交易 成交价为45.41元，相对今日收盘价折价0.70%。该笔交易的买方营业部为方正证券股份有限公司总部， 卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。 证券时报·数据宝统计显示，君实生物-U今日收盘价为45.73元，上涨0.20%，日换手率为2.57%，成交额 为9.09亿元，全天主力资金净流出3762.49万元，近5日该股累计下跌4.19%，近5日资金合计净流出1.71 亿元。 | 成交量 （万 | 成交金额 | 成交价 | 相对当日收盘折 | 买方营业部 | | | --- | --- | --- | --- | --- | --- | | | （万元） | 格 | 溢价（%） | | 卖方营业部 | | 股） | | （元） | | | | | 100.00 | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月18日，君实生物收涨0.20%，收盘价为45.73元，发生1笔大宗交易，合计成交量100万股，成交金额 4541万元。 进一步统计，近3个月内该股累计发生10笔大宗交易，合计成交金额为4.71亿元。该股近5个交易日累计 下跌4.19%，主力资金合计净流出1.75亿元。 责任编辑：小浪快报 第1笔成交价格为45.41元，成交100.00万股，成交金额4,541.00万元，溢价率为-0.70%，买方营业部为方 正证券股份有限公司总部，卖方营业部为中信证券股份有限公司上海浦东新区东方路证券营业部。 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and other services (0.59%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2]. - Junshi is advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Vaccine Development - The company is collaborating with various research institutions to develop vaccines, including monkeypox and Zika vaccines, which are currently in preclinical development [3]. - A partnership with Peking University and other institutions has been established to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the first half of 2025, Junshi Biosciences reported revenue of 1.168 billion yuan, a year-on-year increase of 48.64%, while the net profit attributable to shareholders was -413 million yuan, reflecting a 36.01% increase [8]. - As of June 30, 2025, the number of shareholders increased by 5.88% to 31,200, with a decrease in average circulating shares per person by 5.56% [8]. Market Activity - On September 18, the stock price of Junshi Biosciences increased by 0.20%, with a trading volume of 909 million yuan and a turnover rate of 2.57%, resulting in a total market capitalization of 46.951 billion yuan [1]. - Recent trading activity indicates a net outflow of 31.6178 million yuan from main funds, with a lack of clear trends in main fund movements [4][5].

Core Points - The stock price of Junshi Biosciences has increased by 70.44% year-to-date, with a recent decline of 2.41% over the last five trading days [2] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, a year-on-year increase of 36.01% [2] Company Overview - Junshi Biosciences, established on December 27, 2012, is located in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The main revenue sources for the company are drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2] Stock Performance and Market Activity - As of September 18, the stock price was 46.58 yuan per share, with a market capitalization of 47.823 billion yuan [1] - The trading volume on September 18 was 151 million yuan, with a turnover rate of 0.43% [1] - Institutional holdings show that the top ten circulating shareholders include various ETFs, with notable changes in shareholding [3]

9月17日，君实生物大宗交易成交100万股，成交额4532万元，占当日总成交额的6.05%，成交价45.32 元，较市场收盘价45.64元折价0.7%。 | 025-09-17 | 君实生物 | 688180 | 45.32 4532 | 100 | 方正证券股份有限 公司总部 | 中信证券股份有限 公司上海浦东新区 CALL COLLECT COLLECTION COLLECTION CONSULTER OF CLAINS | 결 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | ...

Group 1 - The Hong Kong innovative drug concept stocks experienced a significant decline on September 17, with major companies like China Biologic Products, Weiya Bio, and Fosun Pharma dropping over 4% [1] - Other companies such as Junshi Biosciences, Rongchang Biopharma, and Innovent Biologics also saw declines exceeding 3% [1]